Pharma pricing policy detrimental for industry: Biocon
The government's pricing policy for the pharma sector, which will bring 348 drugs under price control, will be detrimental for the domestic pharmaceutical industry, says Kiran Mazumdar Shaw, CMD of Biocon. She adds that while the benefits of the policy in bringing down drug prices will be limited, the impact on profitability and sustainability of the Indian pharma industry will be seriously dented.
